L'intérêt à découvert pour SAB Biotherapeutics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de SAB Biotherapeutics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

SAB Biotherapeutics (NASDAQ:SABS) Stock, Rapport sur les intérêts à découvert

SAB Biotherapeutics

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

SAB Biotherapeutics Inc

UBS analyst Jay Sole maintains VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) with a Neutral and raises the price target from $24 to $28.

News

Price Target

Analyst Ratings

UBS Maintains Neutral on VF, Raises Price Target to $28

UBS analyst Lloyd Walmsley maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $736 to $786.

UBS Maintains Buy on Meta Platforms, Raises Price Target to $786

UBS analyst Joseph Spak maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Sell and raises the price target from $226 to $259.

TSLA

UBS Maintains Sell on Tesla, Raises Price Target to $259

UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and raises the price target from $162 to $176.

NBIX

UBS Maintains Buy on Neurocrine Biosciences, Raises Price Target to $176

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) has outperformed the market over the past 5 years by 2.84% on an annualized basis producing an average annual return of 15.8%. Currently, AbbVie has a market capitalization of $310.89 billion. 
Buying $100 In ABBV: If an investor had bought $100 of ABBV stock 5 years ago, it would be worth $213.43 today based on a price of $175.93 for ABBV at the time of writing.
<h3>AbbVie's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738278910_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

ABBV

$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today

TD Securities analyst Craig Hutchison maintains MAG Silver (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MAG#TSX">MAG</a>) with a Buy and raises the price target from C$26 to C$27.

TSX:MAG

TD Securities Maintains Buy on MAG Silver, Raises Price Target to C$27

TD Securities analyst Daniel Chan maintains CGI (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GIB#TSX">GIB</a>) with a Buy and raises the price target from C$180 to C$190.

TSX:GIB

TSX:GIB/A

TD Securities Maintains Buy on CGI, Raises Price Target to C$190

Citigroup analyst Ronald Josey maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $753 to $780.

Citigroup Maintains Buy on Meta Platforms, Raises Price Target to $780

Citigroup analyst Jon Tower maintains Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) with a Neutral and raises the price target from $166 to $185.

Citigroup Maintains Neutral on Brinker International, Raises Price Target to $185

Citigroup analyst Scott Gruber maintains Seadrill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDRL#NYSE">SDRL</a>) with a Buy and lowers the price target from $50 to $46.

SDRL

Citigroup Maintains Buy on Seadrill, Lowers Price Target to $46

American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) has outperformed the market over the past 5 years by 6.37% on an annualized basis producing an average annual return of 19.32%. Currently, American Express has a market capitalization of $223.90 billion. 
Buying $100 In AXP: If an investor had bought $100 of AXP stock 5 years ago, it would be worth $243.47 today based on a price of $318.95 for AXP at the time of writing.
<h3>American Express's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738278015_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning American Express Stock In The Last 5 Years

Citigroup analyst Scott Gruber maintains Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) with a Neutral and raises the price target from $47 to $48.

Citigroup Maintains Neutral on Valaris, Raises Price Target to $48

Citigroup analyst Asiya Merchant maintains Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Buy and lowers the price target from $82 to $80.

Citigroup Maintains Buy on Western Digital, Lowers Price Target to $80

Citigroup analyst Patrick Donnelly maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and lowers the price target from $285 to $265.

Citigroup Maintains Buy on Danaher, Lowers Price Target to $265

Citigroup analyst George Choi maintains Las Vegas Sands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) with a Buy and raises the price target from $64.5 to $67.

Citigroup Maintains Buy on Las Vegas Sands, Raises Price Target to $67

Maxim Group analyst Jason McCarthy maintains Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) with a Buy and raises the price target from $8 to $12.

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Maxim Group Maintains Buy on Alterity Therapeutics, Raises Price Target to $12

Earnings

HFBL

CORRECTION: Home Federal Bancorp Q2 EPS $0.33, Flat YoY

Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) has outperformed the market over the past 5 years by 18.24% on an annualized basis producing an average annual return of 31.2%. Currently, Cheniere Energy has a market capitalization of $51.65 billion. 
Buying $1000 In LNG: If an investor had bought $1000 of LNG stock 5 years ago, it would be worth $3,918.96 today based on a price of $230.20 for LNG at the time of writing.
<h3>Cheniere Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738277138_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Cheniere Energy 5 Years Ago Would Be Worth This Much Today

Shares of Common Stock are expected to begin trading on the New York Stock Exchange under the ticker symbol "INR." The offering is expected to close on February 3, 2025, subject to customary closing conditions.

IPOs

Infinity Natural Resources Prices Public Offering Of 13.25M Shares Of Class A Common Stock At $20.00 Per Share

Maxim Group analyst Allen Klee initiates coverage on Orangekloud Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) with a Buy rating and announces Price Target of $5.

Initiation

ORKT

Maxim Group Initiates Coverage On Orangekloud Technology with Buy Rating, Announces Price Target of $5

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SAB Biotherapeutics (SABS – Research Report) and Vor...

Analysts Offer Insights on Healthcare Companies: SAB Biotherapeutics (SABS) and Vor Biopharma (VOR)

In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on SAB Biotherapeutics (SABS – Research Report), with a price ...

SAB Biotherapeutics (SABS) Gets a Buy from Oppenheimer

Craig-Hallum analyst Albert Lowe maintained a Buy rating on SAB Biotherapeutics (SABS – Research Report) today and set a price target of $11.00. Th...

Craig-Hallum Remains a Buy on SAB Biotherapeutics (SABS)

SAB Biotherapeutics GAAP EPS of -$1.12

Oppenheimer analyst Leland Gershell maintained a Buy rating on SAB Biotherapeutics (SABS – Research Report) today and set a price target of $12.00....

Oppenheimer Sticks to Their Buy Rating for SAB Biotherapeutics (SABS)

The year is winding down, but the bull markets are still charging ahead, getting a boost from improved sentiment after the presidential election. W...

These 2 "Strong Buy" Penny Stocks Are Set to Triple (or more), Say Analysts

Craig-Hallum analyst Albert Lowe maintained a Buy rating on SAB Biotherapeutics (SABS – Research Report) today. The company's shares closed yesterd...

SAB Biotherapeutics (SABS) Gets a Buy from Craig-Hallum

SAB BIO announced positive topline data from a Phase 1 trial of SAB-142 in a single-ascending dose among healthy volunteers. The study met its prim...

SAB Biotherapeutics announces data from Phase 1 trial of SAB-142

In a report released today, Albert Lowe from Craig-Hallum maintained a Buy rating on SAB Biotherapeutics (SABS – Research Report). The company's sh...

In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on SAB Biotherapeutics (SABS – Research Report), with a price...

Comments

SAB Biotherapeutics

Intérêt court

SAB Biotherapeutics (NASDAQ:SABS) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL